Ipratropium Steri-Neb (Ipratropium Bromide)

Ipratropium Steri-Neb is an anticholinergic bronchodilator used in the management of obstructive airway diseases.

• Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations.
• Asthma: provides additional bronchodilation when used with other controller therapies.
• Bronchospasm: offers rapid relief of acute bronchoconstriction associated with COPD or asthma.

• Ipratropium bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M3) on airway smooth muscle. By blocking acetylcholine‑mediated bronchoconstriction, it prevents calcium influx into smooth‑muscle cells, leading to relaxation of the bronchial passages and increased airway caliber.

Ipratropium Steri-Neb may cause a range of adverse reactions.

Common Side Effects

• Cough: mild to moderate irritation of the throat during inhalation.
• Dry mouth: reduced salivation due to anticholinergic activity.
• Throat irritation: discomfort or soreness after use.
• Headache: transient mild headache.
• Dizziness: occasional light‑headed sensation.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Paradoxical bronchospasm: worsening of breathing difficulty.
• Allergic reaction: rash, itching, or hives.
• Angioedema: swelling of lips, tongue, or face.
• Severe cough: persistent, distressing cough.
• Respiratory infection: increased susceptibility to lung infections.
• Anaphylaxis: rare life‑threatening systemic reaction.

Before prescribing Ipratropium Steri-Neb, clinicians should consider several safety measures.

• Assess renal function: dose adjustment may be needed in severe impairment.
• Monitor anticholinergic load: watch for dry mouth, urinary retention, or blurred vision.
• Use with caution in glaucoma: intra‑ocular pressure may increase.
• Avoid in patients with known hypersensitivity to ipratropium or formulation components.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Ipratropium bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Other anticholinergic agents: additive anticholinergic effects may increase risk of dry mouth, urinary retention, or constipation.
• MAO inhibitors: potential for enhanced cholinergic blockade (rare but reported).

Moderate Interactions (Monitor Closely):\n- Beta‑2 agonists: may have synergistic bronchodilation; monitor for excessive bronchodilation.

• Tricyclic antidepressants: increased anticholinergic burden.
• Antihistamines: additive drying of secretions.
• Cholinesterase inhibitors (e.g., donepezil): may reduce therapeutic effect of ipratropium.
• Diuretics: monitor for electrolyte disturbances if severe dehydration occurs.